首页 > 最新文献

Asian Pacific journal of allergy and immunology最新文献

英文 中文
Thymocytes induce renal tubular epithelial cells to undergo the epithelial-to-mesenchymal transition. 胸腺细胞诱导肾小管上皮细胞发生上皮到间质的转变。
IF 2.3 4区 医学 Q3 ALLERGY Pub Date : 2025-03-01 DOI: 10.12932/AP-210221-1075
Huajun Sun, Xueyao Wang, Yisha Liu, Shuaixia Yu, Yue Yang, Shan Wu, Chengbin Zhang

Background: Renal tubulointerstitial fibrosis is known to occur as a result of epithelial cell transformation into myofibroblasts via the epithelial-to-mesenchymal transition (EMT) process. It has been reported that macrophages, regulatory T (Treg) cells, and gamma delta T (γδ T) cells can promote fibrosis via EMT in vivo.

Objective: Our study intended to detect whether thymocytes can induce renal tubular cells to undergo the EMT.

Methods: Rat thymocytes were activated by phytohemagglutinin and concanavalin A. The rat renal tubular epithelial cells (NRK-52E) were incubated in a conditioned medium harvested from activated thymocytes or co-cultured with freshly isolated thymocytes for 48 hours. Real-time reverse transcription-polymerase chain reaction, immunofluorescence, and western blotting analysis were used to test the expression of the epithelial and mesenchymal markers in NRK-52E cells. Scratch assay was designed to test the cell migration abilities of NRK-52E cells. Student's t test and oneway analysis of variance test were used for statistical analysis.

Results: The combined stimulation with phytohemagglutinin and concanavalin A activated the primary isolated rat thymocytes. After treatment with conditioned medium or freshly isolated thymocytes, the expression levels of cytokeratin 19 and E-cadherin were downregulated in NRK-52E cells, while the mRNA and protein expression levels of alpha-smooth muscle actin, desmin, and vimentin were upregulated (P < 0.05). We found that the cell migration abilities of the induced NRK-52E cells were significantly improved.

Conclusions: Both activated rat thymocytes (more percentage of CD8+ T cells) and freshly isolated thymocytes have promoting effects on the EMT of NRK-52E cells.

背景:众所周知,肾小管间质纤维化是上皮细胞通过上皮-间质转化(EMT)过程转变为肌成纤维细胞的结果。据报道,巨噬细胞、调节性 T(Treg)细胞和γδT(γδT)细胞可通过 EMT 促进体内纤维化:我们的研究旨在检测胸腺细胞是否能诱导肾小管细胞发生 EMT:大鼠肾小管上皮细胞(NRK-52E)在从活化的胸腺细胞中获得的条件培养基中或与新鲜分离的胸腺细胞共培养48小时。采用实时逆转录聚合酶链反应、免疫荧光和 Western 印迹分析检测 NRK-52E 细胞中上皮和间质标记物的表达。划痕实验用于检测 NRK-52E 细胞的迁移能力。统计分析采用学生 t 检验和单向方差分析:结果:植物血凝素和 concanavalin A 的联合刺激激活了原代离体大鼠胸腺细胞。经条件培养基或新鲜分离的胸腺细胞处理后,NRK-52E细胞中细胞角蛋白19和E-cadherin的表达水平下调,而α-平滑肌肌动蛋白、desmin和波形蛋白的mRNA和蛋白表达水平上调(P < 0.05)。我们发现,诱导的 NRK-52E 细胞的细胞迁移能力明显提高:结论:活化的大鼠胸腺细胞(CD8+ T 细胞比例更高)和新鲜分离的胸腺细胞都对 NRK-52E 细胞的 EMT 有促进作用。
{"title":"Thymocytes induce renal tubular epithelial cells to undergo the epithelial-to-mesenchymal transition.","authors":"Huajun Sun, Xueyao Wang, Yisha Liu, Shuaixia Yu, Yue Yang, Shan Wu, Chengbin Zhang","doi":"10.12932/AP-210221-1075","DOIUrl":"10.12932/AP-210221-1075","url":null,"abstract":"<p><strong>Background: </strong>Renal tubulointerstitial fibrosis is known to occur as a result of epithelial cell transformation into myofibroblasts via the epithelial-to-mesenchymal transition (EMT) process. It has been reported that macrophages, regulatory T (Treg) cells, and gamma delta T (γδ T) cells can promote fibrosis via EMT in vivo.</p><p><strong>Objective: </strong>Our study intended to detect whether thymocytes can induce renal tubular cells to undergo the EMT.</p><p><strong>Methods: </strong>Rat thymocytes were activated by phytohemagglutinin and concanavalin A. The rat renal tubular epithelial cells (NRK-52E) were incubated in a conditioned medium harvested from activated thymocytes or co-cultured with freshly isolated thymocytes for 48 hours. Real-time reverse transcription-polymerase chain reaction, immunofluorescence, and western blotting analysis were used to test the expression of the epithelial and mesenchymal markers in NRK-52E cells. Scratch assay was designed to test the cell migration abilities of NRK-52E cells. Student's t test and oneway analysis of variance test were used for statistical analysis.</p><p><strong>Results: </strong>The combined stimulation with phytohemagglutinin and concanavalin A activated the primary isolated rat thymocytes. After treatment with conditioned medium or freshly isolated thymocytes, the expression levels of cytokeratin 19 and E-cadherin were downregulated in NRK-52E cells, while the mRNA and protein expression levels of alpha-smooth muscle actin, desmin, and vimentin were upregulated (P < 0.05). We found that the cell migration abilities of the induced NRK-52E cells were significantly improved.</p><p><strong>Conclusions: </strong>Both activated rat thymocytes (more percentage of CD8+ T cells) and freshly isolated thymocytes have promoting effects on the EMT of NRK-52E cells.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"111-123"},"PeriodicalIF":2.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39171749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Elevation of anti-elastin antibody in patients with asthma. 哮喘患者体内的抗弹性蛋白抗体升高。
IF 2.3 4区 医学 Q3 ALLERGY Pub Date : 2025-03-01 DOI: 10.12932/AP-010221-1052
Shingo Tokita, Kumiya Sugiyama, Tomoshige Wakayama, Hajime Arifuku, Naotatsu Otsuji, Kei Sugitate, Takayoshi Owada, Kenya Koyama, Hirokuni Hirata, Masafumi Arima, Yoshihiko Ueda, Yasutsugu Fukushima

Background: It is often difficult to differentiate between asthma and chronic obstructive pulmonary disease (COPD), and useful biomarkers are needed for accurate diagnosis.

Objective: We evaluated anti-elastin antibody to identify useful biomarkers for differentiating between a diagnosis of asthma and COPD.

Methods: Patients with asthma (male to female ratio = 10/13; mean age, 67.3 years), COPD (16/0; 74.8 years) and controls (8/4; 72.3 years) were enrolled. Samples from sputum and serum were collected and levels of anti-elastin Ab were measured.

Results: The levels of anti-elastin Ab in sputum were significantly higher in asthma (11.4 ± 7.16 μg/mL) than in COPD (5.82 ± 5.16 μg/mL; P < 0.01), and serum levels in asthma (67.4 ± 29.7 μg/mL) were also significantly higher than in COPD or controls (45.0 ± 12.8 μg/mL; P < 0.05, 38.6 ± 10.4 μg/mL; P < 0.01, respectively). Anti-elastin Ab in sputum showed a positive correlation with smoking in asthma (r2 = 0.218, P < 0.05). However, no significant differences were observed in the levels of anti-elastin Ab and eosinophils, asthma phenotypes, inhaled corticosteroids, or severity in patients with asthma. Elastin was strongly expressed under the airway basement membrane in asthma compared with COPD or the healthy control.

Conclusions: Anti-elastin Ab in sputum could be a useful biomarker for COPD and asthma in ever-smokers. In asthma, anti-elastin Ab was recruited to the airways by both airway allergic inflammation and smoking, and it may contribute to the progression of airway remodeling via autoimmune inflammation, but not emphysema, in COPD.

背景:通常很难区分哮喘和慢性阻塞性肺病(COPD),因此需要有用的生物标志物来进行准确诊断:我们评估了抗弹性蛋白抗体,以确定区分哮喘和慢性阻塞性肺疾病诊断的有用生物标志物:方法:我们招募了哮喘患者(男女比例=10/13;平均年龄 67.3 岁)、慢性阻塞性肺病患者(16/0;74.8 岁)和对照组患者(8/4;72.3 岁)。采集痰液和血清样本并测定抗弹性蛋白抗体水平:哮喘患者痰中抗弹性蛋白抗体水平(11.4 ± 7.16 μg/mL)明显高于慢性阻塞性肺病患者(5.82 ± 5.16 μg/mL;P <0.01),哮喘患者血清中抗弹性蛋白抗体水平(67.4 ± 29.7 μg/mL)也明显高于COPD或对照组(分别为45.0 ± 12.8 μg/mL;P < 0.05,38.6 ± 10.4 μg/mL;P < 0.01)。痰中的抗弹性蛋白抗体与哮喘患者吸烟呈正相关(r2 = 0.218,P < 0.05)。然而,在哮喘患者的抗弹性蛋白抗体和嗜酸性粒细胞水平、哮喘表型、吸入皮质类固醇或严重程度方面均未观察到明显差异。与慢性阻塞性肺病或健康对照组相比,哮喘患者气道基底膜下的弹性蛋白表达较强:结论:痰中的抗弹性蛋白抗体可作为慢性阻塞性肺病和哮喘的有效生物标志物。在哮喘患者中,气道过敏性炎症和吸烟都会将抗弹性蛋白Ab招募到气道中,它可能会通过自身免疫性炎症导致气道重塑,但不会导致慢性阻塞性肺病患者的肺气肿。
{"title":"Elevation of anti-elastin antibody in patients with asthma.","authors":"Shingo Tokita, Kumiya Sugiyama, Tomoshige Wakayama, Hajime Arifuku, Naotatsu Otsuji, Kei Sugitate, Takayoshi Owada, Kenya Koyama, Hirokuni Hirata, Masafumi Arima, Yoshihiko Ueda, Yasutsugu Fukushima","doi":"10.12932/AP-010221-1052","DOIUrl":"10.12932/AP-010221-1052","url":null,"abstract":"<p><strong>Background: </strong>It is often difficult to differentiate between asthma and chronic obstructive pulmonary disease (COPD), and useful biomarkers are needed for accurate diagnosis.</p><p><strong>Objective: </strong>We evaluated anti-elastin antibody to identify useful biomarkers for differentiating between a diagnosis of asthma and COPD.</p><p><strong>Methods: </strong>Patients with asthma (male to female ratio = 10/13; mean age, 67.3 years), COPD (16/0; 74.8 years) and controls (8/4; 72.3 years) were enrolled. Samples from sputum and serum were collected and levels of anti-elastin Ab were measured.</p><p><strong>Results: </strong>The levels of anti-elastin Ab in sputum were significantly higher in asthma (11.4 ± 7.16 μg/mL) than in COPD (5.82 ± 5.16 μg/mL; P < 0.01), and serum levels in asthma (67.4 ± 29.7 μg/mL) were also significantly higher than in COPD or controls (45.0 ± 12.8 μg/mL; P < 0.05, 38.6 ± 10.4 μg/mL; P < 0.01, respectively). Anti-elastin Ab in sputum showed a positive correlation with smoking in asthma (r2 = 0.218, P < 0.05). However, no significant differences were observed in the levels of anti-elastin Ab and eosinophils, asthma phenotypes, inhaled corticosteroids, or severity in patients with asthma. Elastin was strongly expressed under the airway basement membrane in asthma compared with COPD or the healthy control.</p><p><strong>Conclusions: </strong>Anti-elastin Ab in sputum could be a useful biomarker for COPD and asthma in ever-smokers. In asthma, anti-elastin Ab was recruited to the airways by both airway allergic inflammation and smoking, and it may contribute to the progression of airway remodeling via autoimmune inflammation, but not emphysema, in COPD.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"49-55"},"PeriodicalIF":2.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39172752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence and diagnostic values of laboratory animal allergy among research personnel. 研究人员对实验动物过敏的发生率和诊断价值。
IF 2.3 4区 医学 Q3 ALLERGY Pub Date : 2025-03-01 DOI: 10.12932/AP-220321-1094
Sung-Yoon Kang, Ha-Kyeong Won, So-Young Park, Shuaixia Yu, Sang Min Lee, Sang Pyo Lee

Background: Laboratory animal allergy (LAA) has not been sufficiently investigated, although LAA is a relatively common work-related condition and important occupational hazard.

Objective: This study aimed to evaluate the prevalence of LAA and analyze the diagnostic value of serum specific IgE (sIgE) using the skin prick test (SPT) as a comparative standard.

Methods: Korean laboratory animal researchers who attended an annual symposium were requested to answer questionnaires regarding demographic characteristics, laboratory animal exposure, and symptoms related to laboratory animal exposure. A total of 213 participants underwent a SPT with mouse and rat epithelial allergen extract. We measured sIgE against rodent urine, epithelium, and serum allergens from 63 participants. SPT outcome served as the comparison method.

Results: Among 223 participants, 213 had direct/indirect exposure to mice or rats, and 30% and 14% of them complained of allergic symptoms after exposure to mouse and rat, respectively. Sensitization rates were 28% for mouse epithelium and 23% for rat epithelium. Compared to a positive SPT with wheal ≥ 3 mm, presence of sIgE against rodent allergens showed a higher positive predictive value of 87-91% at a cut-off level of 0.35 KUA/L. Agreement between SPT and sIgE test was determined to be fair to moderate.

Conclusions: Sensitization and allergy to mouse and rat were prevalent among laboratory personnel in Korea. When evaluating cases of potential LAA, the sIgE test can provide added diagnostic value if the skin test is positive. Careful interpretation of two tests is required to accurately diagnose LAA.

背景:尽管实验动物过敏(LAA)是一种相对常见的工作相关疾病和重要的职业危害,但尚未对其进行充分调查:本研究旨在评估 LAA 的患病率,并以皮肤点刺试验(SPT)为比较标准,分析血清特异性 IgE(sIgE)的诊断价值:方法:要求参加年度研讨会的韩国实验动物研究人员回答有关人口统计学特征、实验动物接触情况和实验动物接触相关症状的问卷。共有 213 名与会者接受了小鼠和大鼠上皮过敏原提取物的 SPT 检测。我们测量了 63 名参与者针对啮齿动物尿液、上皮细胞和血清过敏原的 sIgE。结果:结果:在 223 名参与者中,有 213 人直接或间接接触过小鼠或大鼠,其中 30% 和 14% 的人在接触小鼠和大鼠后出现过敏症状。小鼠上皮细胞的致敏率为 28%,大鼠上皮细胞的致敏率为 23%。在 0.35 KUA/L 的临界值下,啮齿类动物过敏原 sIgE 的阳性预测值为 87%-91%,而 SPT 阳性且乳突≥ 3 mm 的阳性预测值为 87%-91%。SPT 和 sIgE 检测之间的一致性被确定为中等偏上:结论:韩国实验室人员对小鼠和大鼠过敏的情况十分普遍。在评估潜在的 LAA 病例时,如果皮试呈阳性,sIgE 试验可提供额外的诊断价值。要准确诊断 LAA,需要对两种检测结果进行仔细解读。
{"title":"Prevalence and diagnostic values of laboratory animal allergy among research personnel.","authors":"Sung-Yoon Kang, Ha-Kyeong Won, So-Young Park, Shuaixia Yu, Sang Min Lee, Sang Pyo Lee","doi":"10.12932/AP-220321-1094","DOIUrl":"10.12932/AP-220321-1094","url":null,"abstract":"<p><strong>Background: </strong>Laboratory animal allergy (LAA) has not been sufficiently investigated, although LAA is a relatively common work-related condition and important occupational hazard.</p><p><strong>Objective: </strong>This study aimed to evaluate the prevalence of LAA and analyze the diagnostic value of serum specific IgE (sIgE) using the skin prick test (SPT) as a comparative standard.</p><p><strong>Methods: </strong>Korean laboratory animal researchers who attended an annual symposium were requested to answer questionnaires regarding demographic characteristics, laboratory animal exposure, and symptoms related to laboratory animal exposure. A total of 213 participants underwent a SPT with mouse and rat epithelial allergen extract. We measured sIgE against rodent urine, epithelium, and serum allergens from 63 participants. SPT outcome served as the comparison method.</p><p><strong>Results: </strong>Among 223 participants, 213 had direct/indirect exposure to mice or rats, and 30% and 14% of them complained of allergic symptoms after exposure to mouse and rat, respectively. Sensitization rates were 28% for mouse epithelium and 23% for rat epithelium. Compared to a positive SPT with wheal ≥ 3 mm, presence of sIgE against rodent allergens showed a higher positive predictive value of 87-91% at a cut-off level of 0.35 KUA/L. Agreement between SPT and sIgE test was determined to be fair to moderate.</p><p><strong>Conclusions: </strong>Sensitization and allergy to mouse and rat were prevalent among laboratory personnel in Korea. When evaluating cases of potential LAA, the sIgE test can provide added diagnostic value if the skin test is positive. Careful interpretation of two tests is required to accurately diagnose LAA.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"34-39"},"PeriodicalIF":2.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39171750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Manila grass (Zoysia matrella) Zoy m 1 allergen may contribute to allergic sensitization in tropical/subtropical regions due to extensive cross-reactivity with other group-1 grass pollen allergens. 马尼拉草(Zoysia matrella)Zoy m 1 过敏原与其他 1 类草花粉过敏原具有广泛的交叉反应性,可能会导致热带/亚热带地区的过敏性疾病。
IF 2.3 4区 医学 Q3 ALLERGY Pub Date : 2025-03-01 DOI: 10.12932/AP-250920-0971
Koravit Somkid, Sirirat Aud-In, Bannapuch Pinkaew, Pongsakorn Tantilipikorn, Surapon Piboonpocanun, Wisuwat Songnuan

Background: Pollen of grasses in Chloridoideae and Panicoideae subfamilies is a major source of grass group-1 allergens in tropical/subtropical areas. Previously, most studies of subtropical grass pollen allergens have focused on Cynodon dactylon (Bermuda grass-Chloridoideae) and Sorghum halepense (Johnson grass-Panicoideae). However, little information is available about allergenicity of pollen from Zoysia matrella (Manila grass or Zoysia grass-Chloridoideae), which is among the most popular turfgrasses in tropical/subtropical areas.

Objective: This study aimed to investigate the IgE reactivity and cross-reactivity of grass group-1 allergen from Z. matrella. In addition, the clinical relevance of Z. matrella in comparison with other species was assessed.

Methods: IgE reactivity and cross-reactivity between recombinant proteins of group-1 allergen from Z. matrella (Zoy m 1) and C. dactylon (Cyn d 1) were determined by ELISA and immunoblot assays. Clinical relevance of Z. matrella pollen in Thai atopic patients was assessed using its pollen crude extract for skin-prick test, in comparison with extracts from four other pollen species.

Results: The Zoy m 1 had high IgE binding and could interfere with binding to C. dactylon crude extract. In addition, Z. matrella pollen extract elicited positive skin-prick test results comparable to previously reported allergenic species. Group-1 grass pollen allergen was confirmed to be a major allergen from Z. matrella among Thai atopic patients and was officially designated Zoy m 1.0101.

Conclusions: Zoy m 1 allergen is a major allergen from Z. matrella that cross-reacts with other group-1 grass pollen allergens in the tropical/subtropical region.

背景:绿草亚科(Chloridoideae)和番杏亚科(Panicoideae)禾本科植物的花粉是热带/亚热带地区 1 类草花粉过敏原的主要来源。以前,对亚热带禾本科花粉过敏原的研究大多集中在百慕大禾本科(Cynodon dactylon)和高粱亚科(Sorghum halepense)。然而,有关热带/亚热带地区最受欢迎的草坪草 Zoysia matrella(马尼拉草或 Zoysia grass-Chloridoideae)花粉过敏性的信息却很少:本研究旨在调查马尼拉草(Zoysia grass-Chloridoideae)草坪草 1 类过敏原的 IgE 反应性和交叉反应性。此外,还评估了马齿苋与其他物种的临床相关性:方法:通过酶联免疫吸附试验和免疫印迹试验测定了马齿苋(Zoy m 1)和C. dactylon(Cyn d 1)1类过敏原重组蛋白的IgE反应性和交叉反应性。使用花粉粗提取物进行皮肤点刺试验,并与其他四种花粉的提取物进行比较,以评估泰国特应性过敏症患者对马齿苋花粉的临床意义:结果:Zoy m 1 与 IgE 的结合率很高,并能干扰与 C. dactylon 粗提取物的结合。此外,Z. matrella花粉萃取物引起的皮肤点刺试验阳性结果与之前报道的致敏物种相当。经证实,泰国特应性疾病患者中的第 1 组草花粉过敏原是来自 Z. matrella 的主要过敏原,并被正式命名为 Zoy m 1.0101:结论:Zoy m 1 过敏原是马齿苋的一种主要过敏原,可与热带/亚热带地区的其他 1 类草花粉过敏原发生交叉反应。
{"title":"Manila grass (Zoysia matrella) Zoy m 1 allergen may contribute to allergic sensitization in tropical/subtropical regions due to extensive cross-reactivity with other group-1 grass pollen allergens.","authors":"Koravit Somkid, Sirirat Aud-In, Bannapuch Pinkaew, Pongsakorn Tantilipikorn, Surapon Piboonpocanun, Wisuwat Songnuan","doi":"10.12932/AP-250920-0971","DOIUrl":"10.12932/AP-250920-0971","url":null,"abstract":"<p><strong>Background: </strong>Pollen of grasses in Chloridoideae and Panicoideae subfamilies is a major source of grass group-1 allergens in tropical/subtropical areas. Previously, most studies of subtropical grass pollen allergens have focused on Cynodon dactylon (Bermuda grass-Chloridoideae) and Sorghum halepense (Johnson grass-Panicoideae). However, little information is available about allergenicity of pollen from Zoysia matrella (Manila grass or Zoysia grass-Chloridoideae), which is among the most popular turfgrasses in tropical/subtropical areas.</p><p><strong>Objective: </strong>This study aimed to investigate the IgE reactivity and cross-reactivity of grass group-1 allergen from Z. matrella. In addition, the clinical relevance of Z. matrella in comparison with other species was assessed.</p><p><strong>Methods: </strong>IgE reactivity and cross-reactivity between recombinant proteins of group-1 allergen from Z. matrella (Zoy m 1) and C. dactylon (Cyn d 1) were determined by ELISA and immunoblot assays. Clinical relevance of Z. matrella pollen in Thai atopic patients was assessed using its pollen crude extract for skin-prick test, in comparison with extracts from four other pollen species.</p><p><strong>Results: </strong>The Zoy m 1 had high IgE binding and could interfere with binding to C. dactylon crude extract. In addition, Z. matrella pollen extract elicited positive skin-prick test results comparable to previously reported allergenic species. Group-1 grass pollen allergen was confirmed to be a major allergen from Z. matrella among Thai atopic patients and was officially designated Zoy m 1.0101.</p><p><strong>Conclusions: </strong>Zoy m 1 allergen is a major allergen from Z. matrella that cross-reacts with other group-1 grass pollen allergens in the tropical/subtropical region.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"25-33"},"PeriodicalIF":2.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39171671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Autologous stem cell transplantation in a patient with systemic sclerosis-associated interstitial lung disease in Taiwan. 台湾一名系统性硬化症相关间质性肺病患者的自体干细胞移植。
IF 2.3 4区 医学 Q3 ALLERGY Pub Date : 2025-03-01 DOI: 10.12932/AP-080421-1108
Yu-Jen Pan, Wei-Han Huang, Kuei-Ying Su

Background: Systemic sclerosis (SSc), characterized by fibrosis of the skin and other organs, is a devastating systemic autoimmune disease. Lung involvement is frequent in SSc and contributes to the high rate of mortality.

Objective: To describe the first case report of SSc and interstitial lung disease (ILD) receiving autologous hematopoietic stem cell transplantation (ASCT) in Taiwan.

Methods: Case report.

Results: A 51-year-old man presented with rapid skin thickening and shortness of breath. Early progressive SSc-associated ILD was diagnosed. Because his lung function rapidly declined and his skin disease progressed, he received ASCT with satisfactory treatment responses in both skin thickness and lung function. In addition, lung imaging analysis showed remarkable improvements in ILD after treatment.

Conclusions: We suggest that ASCT can be considered in selected patients with early, rapidly progressive SSc associated with ILD.

背景:以皮肤和其他器官纤维化为特征的系统性硬化症(SSc)是一种破坏性的系统性自身免疫疾病。肺部受累是 SSc 的常见病,也是导致高死亡率的原因之一:描述台湾首例接受自体造血干细胞移植(ASCT)的SSc合并间质性肺病(ILD)的病例报告:方法:病例报告:结果:一名51岁的男性患者出现皮肤迅速增厚和呼吸急促。确诊为早期进行性 SSc 相关性 ILD。由于他的肺功能急剧下降,皮肤病也在进展,因此他接受了 ASCT 治疗,皮肤厚度和肺功能均取得了令人满意的疗效。此外,肺部成像分析表明,治疗后 ILD 有明显改善:我们建议,对于早期、快速进展的 SSc 合并 ILD 患者,可以考虑进行 ASCT 治疗。
{"title":"Autologous stem cell transplantation in a patient with systemic sclerosis-associated interstitial lung disease in Taiwan.","authors":"Yu-Jen Pan, Wei-Han Huang, Kuei-Ying Su","doi":"10.12932/AP-080421-1108","DOIUrl":"10.12932/AP-080421-1108","url":null,"abstract":"<p><strong>Background: </strong>Systemic sclerosis (SSc), characterized by fibrosis of the skin and other organs, is a devastating systemic autoimmune disease. Lung involvement is frequent in SSc and contributes to the high rate of mortality.</p><p><strong>Objective: </strong>To describe the first case report of SSc and interstitial lung disease (ILD) receiving autologous hematopoietic stem cell transplantation (ASCT) in Taiwan.</p><p><strong>Methods: </strong>Case report.</p><p><strong>Results: </strong>A 51-year-old man presented with rapid skin thickening and shortness of breath. Early progressive SSc-associated ILD was diagnosed. Because his lung function rapidly declined and his skin disease progressed, he received ASCT with satisfactory treatment responses in both skin thickness and lung function. In addition, lung imaging analysis showed remarkable improvements in ILD after treatment.</p><p><strong>Conclusions: </strong>We suggest that ASCT can be considered in selected patients with early, rapidly progressive SSc associated with ILD.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"106-110"},"PeriodicalIF":2.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39434838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Validity and reliability of the Indonesian version of the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL). 印尼版慢性荨麻疹生活质量问卷(CU-Q2oL)的有效性和可靠性。
IF 2.3 4区 医学 Q3 ALLERGY Pub Date : 2025-03-01 DOI: 10.12932/AP-291220-1024
Teffy Nuary, Windy Keumala Budianti, Wresti Indriatmi, Ilaria Baiardini

Background: Assessment of quality of life is needed to assess therapeutic response. There is currently no instrument available for assessing the quality of life of chronic urticaria patients in Indonesia. CU-Q2oL is a specific questionnaire for chronic urticaria that was first developed in Italian. Validity and reliability tests are important to ensure that the language or term used are appropriate to the local culture and there is no change in the validity and reliability of the questionnaire.

Objective: The aim of this study is to develop an Indonesian version of CU-Q2oL.

Methods: The Italian version CU-Q2oL was translated into Indonesian and underwent cross-cultural adaptation. The translated questionnaire was completed online by 40 chronic urticaria patients of the Dermatovenereology Outpatient Clinic of the Cipto Mangunkusumo General Hospital, Jakarta, Indonesia.

Results: Validity test resulted in correlation coefficient values for all questions of 0.467 to 0.856. Reliability test showed a Cronbach's α coefficient of all questions of 0.923 and the intraclass correlation coefficient (ICC) for all questions was 0.913.

Conclusions: This study demonstrates that the Indonesian CU-Q2oL questionnaire is valid, reliable, and suitable to assess the quality of life of chronic urticaria patients in Indonesia.

背景:评估治疗反应需要对生活质量进行评估。在印度尼西亚,目前还没有用于评估慢性荨麻疹患者生活质量的工具。CU-Q2oL 是一份专门针对慢性荨麻疹的问卷,最初是用意大利语编制的。有效性和可靠性测试对于确保所使用的语言或术语适合当地文化以及问卷的有效性和可靠性没有变化非常重要:本研究旨在开发印尼语版的 CU-Q2oL:方法:将意大利语版 CU-Q2oL 翻译成印尼语,并进行跨文化调整。印度尼西亚雅加达 Cipto Mangunkusumo 综合医院皮肤性病学门诊的 40 名慢性荨麻疹患者在线填写了翻译后的问卷:有效性测试结果显示,所有问题的相关系数为 0.467 至 0.856。可靠性测试表明,所有问题的 Cronbach's α 系数为 0.923,所有问题的类内相关系数(ICC)为 0.913:本研究表明,印尼 CU-Q2oL 问卷有效、可靠,适用于评估印尼慢性荨麻疹患者的生活质量。
{"title":"Validity and reliability of the Indonesian version of the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL).","authors":"Teffy Nuary, Windy Keumala Budianti, Wresti Indriatmi, Ilaria Baiardini","doi":"10.12932/AP-291220-1024","DOIUrl":"10.12932/AP-291220-1024","url":null,"abstract":"<p><strong>Background: </strong>Assessment of quality of life is needed to assess therapeutic response. There is currently no instrument available for assessing the quality of life of chronic urticaria patients in Indonesia. CU-Q2oL is a specific questionnaire for chronic urticaria that was first developed in Italian. Validity and reliability tests are important to ensure that the language or term used are appropriate to the local culture and there is no change in the validity and reliability of the questionnaire.</p><p><strong>Objective: </strong>The aim of this study is to develop an Indonesian version of CU-Q2oL.</p><p><strong>Methods: </strong>The Italian version CU-Q2oL was translated into Indonesian and underwent cross-cultural adaptation. The translated questionnaire was completed online by 40 chronic urticaria patients of the Dermatovenereology Outpatient Clinic of the Cipto Mangunkusumo General Hospital, Jakarta, Indonesia.</p><p><strong>Results: </strong>Validity test resulted in correlation coefficient values for all questions of 0.467 to 0.856. Reliability test showed a Cronbach's α coefficient of all questions of 0.923 and the intraclass correlation coefficient (ICC) for all questions was 0.913.</p><p><strong>Conclusions: </strong>This study demonstrates that the Indonesian CU-Q2oL questionnaire is valid, reliable, and suitable to assess the quality of life of chronic urticaria patients in Indonesia.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"71-75"},"PeriodicalIF":2.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39171672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prospective Assessment of Penicillin Allergy (PAPA): Evaluating the performance of penicillin allergy testing and post-delabelling outcomes among Hong Kong Chinese. 青霉素过敏的前瞻性评估(PAPA):评估香港华人青霉素过敏试验的表现和去标签后的结果。
IF 2.3 4区 医学 Q3 ALLERGY Pub Date : 2025-03-01 DOI: 10.12932/AP-270922-1469
Tin Sum Li, Harris K S Hui, Andy Ka Chun Kan, Maegan H Y Yeung, Jane C Y Wong, Valerie Chiang, Philip Hei Li

Background: Incorrect penicillin 'allergy' labels predispose patients to adverse outcomes but are under-recognised in many Asian countries. Studies on performance and post-delabelling outcomes of penicillin allergy evaluation among Chinese remain scarce.

Objective: To evaluate the diagnostic performance of allergy testing and post-delabelling outcomes among Chinese patients in a prospective penicillin allergy cohort - Prospective Assessment of Penicillin Allergy (PAPA).

Methods: All adult patients (age ≥ 18 years) who underwent penicillin allergy evaluation between January 2020 to December 2021 were recruited and prospectively reviewed by both medical records and individual interviews at least 6 months after delabelling or allergy confirmation.

Results: Out of 372 patients who completed penicillin allergy evaluation, 335 (90%) patients were delabelled. The overall negative predictive value of penicillin skin testing was 95%, but lower for patients with non-immediate type reactions (88%). History of non-immediate symptom onset (OR = 4.501 [95%CI = 2.085-9.716], p < 0.001) and duration since index reaction (OR = 0.942 [95%CI = 0.899-0.987], p = 0.012) were associated with positive skin testing. After at least 6 months, 60 (18%) of de-labelled patients had received penicillins again without any adverse reactions. Fluoroquinolone-use was significantly lower among delabelled patients compared to those with penicillin allergy (38[11%] vs 11[30%], p = 0.004).

Conclusions: After at least 6 months, one in six delabelled patients already received penicillins again safely, with significantly lower fluoroquinolone usage. None experienced adverse reactions. History of non-immediate onset and shorter duration since index reaction were associated with genuine allergy. In patients with severe non-immediate reactions, skin tests should be supplemented with thorough clinical history and adjunct diagnostic evaluations.

背景:不正确的青霉素“过敏”标签使患者易发生不良后果,但在许多亚洲国家未得到充分认识。关于中国人青霉素过敏评价的表现和去标签后结果的研究仍然很少。目的:评价青霉素过敏前瞻性队列——青霉素过敏前瞻性评估(PAPA)中中国患者过敏试验的诊断性能和去标签后结局。方法:招募所有在2020年1月至2021年12月期间接受青霉素过敏评估的成年患者(年龄≥18岁),并在去标签或过敏确认后至少6个月通过医疗记录和个人访谈进行前瞻性回顾。结果:在372例完成青霉素过敏评估的患者中,335例(90%)患者的标签被删除。青霉素皮试的总体阴性预测值为95%,但非立即型反应患者的阴性预测值较低(88%)。非立即症状发作史(OR = 4.501 [95%CI = 2.085 ~ 9.716], p < 0.001)和指数反应持续时间(OR = 0.942 [95%CI = 0.899 ~ 0.987], p = 0.012)与皮肤试验阳性相关。至少6个月后,60名(18%)去标签患者再次接受青霉素治疗,无任何不良反应。去标签患者氟喹诺酮类药物的使用明显低于青霉素过敏患者(38例[11%]vs 11例[30%],p = 0.004)。结论:至少6个月后,六分之一的去标签患者已经安全地再次接受青霉素治疗,氟喹诺酮类药物的使用显著降低。没有出现不良反应。非立即发病史,自指数反应以来持续时间较短,与真正的过敏有关。对于有严重非立即反应的患者,皮肤试验应辅以全面的临床病史和辅助诊断评估。
{"title":"Prospective Assessment of Penicillin Allergy (PAPA): Evaluating the performance of penicillin allergy testing and post-delabelling outcomes among Hong Kong Chinese.","authors":"Tin Sum Li, Harris K S Hui, Andy Ka Chun Kan, Maegan H Y Yeung, Jane C Y Wong, Valerie Chiang, Philip Hei Li","doi":"10.12932/AP-270922-1469","DOIUrl":"10.12932/AP-270922-1469","url":null,"abstract":"<p><strong>Background: </strong>Incorrect penicillin 'allergy' labels predispose patients to adverse outcomes but are under-recognised in many Asian countries. Studies on performance and post-delabelling outcomes of penicillin allergy evaluation among Chinese remain scarce.</p><p><strong>Objective: </strong>To evaluate the diagnostic performance of allergy testing and post-delabelling outcomes among Chinese patients in a prospective penicillin allergy cohort - Prospective Assessment of Penicillin Allergy (PAPA).</p><p><strong>Methods: </strong>All adult patients (age ≥ 18 years) who underwent penicillin allergy evaluation between January 2020 to December 2021 were recruited and prospectively reviewed by both medical records and individual interviews at least 6 months after delabelling or allergy confirmation.</p><p><strong>Results: </strong>Out of 372 patients who completed penicillin allergy evaluation, 335 (90%) patients were delabelled. The overall negative predictive value of penicillin skin testing was 95%, but lower for patients with non-immediate type reactions (88%). History of non-immediate symptom onset (OR = 4.501 [95%CI = 2.085-9.716], p < 0.001) and duration since index reaction (OR = 0.942 [95%CI = 0.899-0.987], p = 0.012) were associated with positive skin testing. After at least 6 months, 60 (18%) of de-labelled patients had received penicillins again without any adverse reactions. Fluoroquinolone-use was significantly lower among delabelled patients compared to those with penicillin allergy (38[11%] vs 11[30%], p = 0.004).</p><p><strong>Conclusions: </strong>After at least 6 months, one in six delabelled patients already received penicillins again safely, with significantly lower fluoroquinolone usage. None experienced adverse reactions. History of non-immediate onset and shorter duration since index reaction were associated with genuine allergy. In patients with severe non-immediate reactions, skin tests should be supplemented with thorough clinical history and adjunct diagnostic evaluations.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"10-17"},"PeriodicalIF":2.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9661270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Direct healthcare cost comparison of Fluticasone propionate/Salmeterol vs Budesonide/Formoterol Maintenance And Reliever Therapy for moderate/severe asthma: Results from Thailand. 丙酸氟替卡松/沙美特罗与布地奈德/福莫特罗中度/重度哮喘维持和缓解疗法的直接医疗成本比较:泰国的研究结果。
IF 2.3 4区 医学 Q3 ALLERGY Pub Date : 2025-03-01 DOI: 10.12932/AP-180421-1117
Torsak Bunupuradah, Watchara Boonsawat, Jatupum Kamrapit, Bhumika Aggarwal

Background: Inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) for moderate/severe asthma i.e. regular Fluticasone propionate/Salmeterol (FP/Salm) with as-needed short acting beta-2 agonist (SABA) or ICS/Formoterol Maintenance And Reliever Therapy (MART) are the recommended options.

Objective: To compare healthcare cost between regular FP/Salm with as-needed SABA vs MART in Thailand.

Methods: Direct healthcare cost data from 3 published randomized trials in asthma patients aged ≥12 years comparing regular twice-daily FP/Salm with as-needed SABA vs Budesonide/Formoterol (BUD/Form) MART in moderate/severe asthma were considered: AHEAD (NCT00242775/17 countries/2309 patients), COMPASS (AstraZeneca study SD-0390735/16 countries/3335 patients), and COSMOS (AstraZeneca study SD-039-0691/16 countries/2143 patients). Total direct treatment cost comparison/patient/year was calculated as a combination from 1) medication costs plus 2) healthcare utilization costs i.e. cost for health care visit, emergency room visit, and hospitalization. Unit costs referred from National drug information and Health Intervention and Technology Assessment (HITAP), Ministry of Public Health.

Results: Annual medication costs of FP/Salm + SABA were lower than MART in all studies with average cost as 182.01 vs 347.21 USD. Average annual healthcare utilization costs were 17.51 vs 13.01 USD in FP/Salm + SABA and MART, respectively. In overall, total direct treatment costs/patient/year with FP/Salm was 199.53 vs 360.22 USD of MART. Percent saving of total direct treatment costs by FP/Salm + SABA was 45% lower than with MART.

Conclusions: In moderate/severe asthma patients, total direct treatment costs with regular twice-daily FP/Salm with as-needed SABA were lower than with BUD/Form MART primarily due to lower medication costs. Healthcare cost should be considered for asthma care in Thailand.

背景:吸入皮质类固醇/长效β2-受体激动剂(ICS/LABA)治疗中度/重度哮喘,即常规丙酸氟替卡松/沙美特罗(FP/Salm)与按需短效β2-受体激动剂(SABA)或ICS/福莫特罗维持和缓解疗法(MART),是推荐的选择:比较泰国常规 FP/Salm 与按需 SABA 与 MART 的医疗成本:方法:考虑了 3 项已发表的随机试验中的直接医疗成本数据,这些试验针对年龄≥ 12 岁的哮喘患者,比较了中度/重度哮喘患者每日两次常规 FP/Salm 与按需 SABA 与布地奈德/福莫特罗(BUD/Form)MART 的治疗效果:AHEAD(NCT00242775/17个国家/2309名患者)、COMPASS(阿斯利康研究SD-0390735/16个国家/3335名患者)和COSMOS(阿斯利康研究SD-039-0691/16个国家/2143名患者)。直接治疗总成本比较/患者/年的计算方法为:1)药物成本加 2)医疗保健使用成本,即就诊、急诊和住院的成本。单位成本参考了公共卫生部的国家药物信息和健康干预与技术评估(HITAP):在所有研究中,FP/Salm + SABA 的年用药成本均低于 MART,平均成本为 182.01 美元对 347.21 美元。FP/Salm + SABA 和 MART 的年均医疗费用分别为 17.51 美元和 13.01 美元。总体而言,FP/Salm 每名患者每年的直接治疗总费用为 199.53 美元,而 MART 为 360.22 美元。FP/Salm+SABA节省的直接治疗总费用百分比比MART低45%:结论:对于中度/重度哮喘患者,每日两次常规FP/Salm+按需SABA的直接治疗总费用低于BUD/Form MART,主要原因是药物费用较低。泰国的哮喘治疗应考虑医疗成本。
{"title":"Direct healthcare cost comparison of Fluticasone propionate/Salmeterol vs Budesonide/Formoterol Maintenance And Reliever Therapy for moderate/severe asthma: Results from Thailand.","authors":"Torsak Bunupuradah, Watchara Boonsawat, Jatupum Kamrapit, Bhumika Aggarwal","doi":"10.12932/AP-180421-1117","DOIUrl":"10.12932/AP-180421-1117","url":null,"abstract":"<p><strong>Background: </strong>Inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) for moderate/severe asthma i.e. regular Fluticasone propionate/Salmeterol (FP/Salm) with as-needed short acting beta-2 agonist (SABA) or ICS/Formoterol Maintenance And Reliever Therapy (MART) are the recommended options.</p><p><strong>Objective: </strong>To compare healthcare cost between regular FP/Salm with as-needed SABA vs MART in Thailand.</p><p><strong>Methods: </strong>Direct healthcare cost data from 3 published randomized trials in asthma patients aged ≥12 years comparing regular twice-daily FP/Salm with as-needed SABA vs Budesonide/Formoterol (BUD/Form) MART in moderate/severe asthma were considered: AHEAD (NCT00242775/17 countries/2309 patients), COMPASS (AstraZeneca study SD-0390735/16 countries/3335 patients), and COSMOS (AstraZeneca study SD-039-0691/16 countries/2143 patients). Total direct treatment cost comparison/patient/year was calculated as a combination from 1) medication costs plus 2) healthcare utilization costs i.e. cost for health care visit, emergency room visit, and hospitalization. Unit costs referred from National drug information and Health Intervention and Technology Assessment (HITAP), Ministry of Public Health.</p><p><strong>Results: </strong>Annual medication costs of FP/Salm + SABA were lower than MART in all studies with average cost as 182.01 vs 347.21 USD. Average annual healthcare utilization costs were 17.51 vs 13.01 USD in FP/Salm + SABA and MART, respectively. In overall, total direct treatment costs/patient/year with FP/Salm was 199.53 vs 360.22 USD of MART. Percent saving of total direct treatment costs by FP/Salm + SABA was 45% lower than with MART.</p><p><strong>Conclusions: </strong>In moderate/severe asthma patients, total direct treatment costs with regular twice-daily FP/Salm with as-needed SABA were lower than with BUD/Form MART primarily due to lower medication costs. Healthcare cost should be considered for asthma care in Thailand.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"65-70"},"PeriodicalIF":2.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39432382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of the clinical performance of four fungus-specific immunoglobulin E detection systems in patients with Aspergillus allergy. 评估四种真菌特异性免疫球蛋白 E 检测系统对曲霉菌过敏患者的临床效果。
IF 2.3 4区 医学 Q3 ALLERGY Pub Date : 2025-03-01 DOI: 10.12932/AP-161220-1015
Zhifeng Huang, Wanjia Li, Hao Chen, Baoqing Sun

Background: Allergic bronchopulmonary aspergillosis (ABPA) is an airway disease caused by Aspergillus (mainly Aspergillus fumigatus).

Objective: To evaluate the diagnostic performance of four fungal-related allergen-specific immunoglobulin E (sIgE) detection systems.

Methods: A total of 99 patients with ABPA and 30 control patients admitted to the First Affiliated Hospital of Guangzhou Medical University from 2017 to 2019 were included in the study. Four allergen detection systems were used to detect Aspergillus-related sIgE.

Results: The 99 patients were divided into two groups based on the total IgE. Fluorescence immunoassay for fungal mixtures detected positive rates of 100% and 81% in the Confirmed and Probable groups, respectively. For Aspergillus fumigatus, the positive rates were 90.2% and 87.9%, respectively. In the detection of sIgE of fungal mixtures in all ABPA patients, the sensitivity of System 1 was 90.9%, which was higher than for the other three systems (System 2, 38.4%; System 3, 44.4%; System 4, 52.5%), All four systems have excellent specificity ( > 90.0%) and had higher consistency in the Confirmed group than in the Probable group (P < 0.05). Consistency for the Aspergillus mixture and Aspergillus fumigatus detected by fluorescence immunoassay was 90.2% and 86.2% in the Confirmed and Probable groups, respectively.

Conclusions: Despite the many methods used to detect fungal-related sIgE, the ImmunoCAP system has the best clinical diagnostic performance. It is recommended that this method be used to detect fungal (mixtures or Aspergillus fumigatus) sIgE in order to reduce the missed diagnosis rate of ABPA.

背景:过敏性支气管肺曲霉菌病(ABPA)是由曲霉菌(主要是烟曲霉菌)引起的气道疾病:评估四种真菌相关过敏原特异性免疫球蛋白E(sIgE)检测系统的诊断性能:研究共纳入2017年至2019年广州医科大学附属第一医院收治的99例ABPA患者和30例对照组患者。采用四种过敏原检测系统检测曲霉菌相关sIgE:根据总IgE将99名患者分为两组。荧光免疫测定法检测真菌混合物的阳性率在确诊组和可能组分别为 100%和 81%。曲霉菌的阳性率分别为 90.2% 和 87.9%。在检测所有 ABPA 患者的真菌混合物 sIgE 时,系统 1 的灵敏度为 90.9%,高于其他三个系统(系统 2,38.4%;系统 3,44.4%;系统 4,52.5%)。用荧光免疫测定法检测曲霉混合物和烟曲霉的一致性在确诊组和可能组中分别为 90.2% 和 86.2%:尽管检测真菌相关 sIgE 的方法很多,但 ImmunoCAP 系统的临床诊断效果最好。建议使用该方法检测真菌(混合物或烟曲霉)sIgE,以降低 ABPA 的漏诊率。
{"title":"Evaluation of the clinical performance of four fungus-specific immunoglobulin E detection systems in patients with Aspergillus allergy.","authors":"Zhifeng Huang, Wanjia Li, Hao Chen, Baoqing Sun","doi":"10.12932/AP-161220-1015","DOIUrl":"10.12932/AP-161220-1015","url":null,"abstract":"<p><strong>Background: </strong>Allergic bronchopulmonary aspergillosis (ABPA) is an airway disease caused by Aspergillus (mainly Aspergillus fumigatus).</p><p><strong>Objective: </strong>To evaluate the diagnostic performance of four fungal-related allergen-specific immunoglobulin E (sIgE) detection systems.</p><p><strong>Methods: </strong>A total of 99 patients with ABPA and 30 control patients admitted to the First Affiliated Hospital of Guangzhou Medical University from 2017 to 2019 were included in the study. Four allergen detection systems were used to detect Aspergillus-related sIgE.</p><p><strong>Results: </strong>The 99 patients were divided into two groups based on the total IgE. Fluorescence immunoassay for fungal mixtures detected positive rates of 100% and 81% in the Confirmed and Probable groups, respectively. For Aspergillus fumigatus, the positive rates were 90.2% and 87.9%, respectively. In the detection of sIgE of fungal mixtures in all ABPA patients, the sensitivity of System 1 was 90.9%, which was higher than for the other three systems (System 2, 38.4%; System 3, 44.4%; System 4, 52.5%), All four systems have excellent specificity ( > 90.0%) and had higher consistency in the Confirmed group than in the Probable group (P < 0.05). Consistency for the Aspergillus mixture and Aspergillus fumigatus detected by fluorescence immunoassay was 90.2% and 86.2% in the Confirmed and Probable groups, respectively.</p><p><strong>Conclusions: </strong>Despite the many methods used to detect fungal-related sIgE, the ImmunoCAP system has the best clinical diagnostic performance. It is recommended that this method be used to detect fungal (mixtures or Aspergillus fumigatus) sIgE in order to reduce the missed diagnosis rate of ABPA.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"18-24"},"PeriodicalIF":2.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39171745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nivolumab-induced diffuse type 2 rhinosinusitis: A case report. Nivolumab引发的弥漫性2型鼻窦炎:病例报告
IF 2.3 4区 医学 Q3 ALLERGY Pub Date : 2025-03-01 DOI: 10.12932/AP-240721-1196
Firas Kassem, Yossi Rosman, Ilan Blau, Ben Nageris, Anna Zakharov, Ameen Biadsee

Background: Nivolumab, an immune checkpoint inhibitor is used to treat advanced metastatic malignancies. Data showed that nivolumab can cause exacerbated response of T-Helper 2 cells and lead to airway inflammation.

Objective: To present the upper airway findings of a 69-year-old woman after treatment with nivolumab.

Methods: Case report.

Results: A 69-year old woman with no history of chronic rhinosinusitis developed complaints of nasal congestion, rhinorrhea, sneezing, and anosmia. These symptoms started after one year of treatment with nivolumab. Pale polyps were observed on fiberoptic endoscopy examination. A gradual increase in eosinophil blood counts was noted. On histopathology, heavy infiltrates of eosinophils were seen in the tissue.

Conclusions: Nivolumab is used to treat various advanced metastatic malignancies, with a good safety profile. Nevertheless, physicians must be alert to the possibility of evolving type II inflammation in patients, as appropriate therapy can be provided to improve their quality of life.

背景:Nivolumab是一种免疫检查点抑制剂,用于治疗晚期转移性恶性肿瘤。数据显示,尼妥珠单抗可引起T-Helper 2细胞反应加剧,导致气道炎症:介绍一名69岁女性在接受尼妥珠单抗治疗后的上呼吸道检查结果:方法:病例报告:结果:一名没有慢性鼻炎病史的 69 岁女性出现了鼻塞、鼻出血、打喷嚏和嗅觉障碍等症状。这些症状是在使用尼妥珠单抗治疗一年后开始出现的。纤维内窥镜检查发现了浅色息肉。嗜酸性粒细胞计数逐渐增加。组织病理学检查显示,组织中出现大量嗜酸性粒细胞浸润:Nivolumab可用于治疗各种晚期转移性恶性肿瘤,具有良好的安全性。结论:Nivolumab 可用于治疗各种晚期转移性恶性肿瘤,具有良好的安全性,但医生必须警惕患者可能出现的 II 型炎症,因为适当的治疗可以改善患者的生活质量。
{"title":"Nivolumab-induced diffuse type 2 rhinosinusitis: A case report.","authors":"Firas Kassem, Yossi Rosman, Ilan Blau, Ben Nageris, Anna Zakharov, Ameen Biadsee","doi":"10.12932/AP-240721-1196","DOIUrl":"10.12932/AP-240721-1196","url":null,"abstract":"<p><strong>Background: </strong>Nivolumab, an immune checkpoint inhibitor is used to treat advanced metastatic malignancies. Data showed that nivolumab can cause exacerbated response of T-Helper 2 cells and lead to airway inflammation.</p><p><strong>Objective: </strong>To present the upper airway findings of a 69-year-old woman after treatment with nivolumab.</p><p><strong>Methods: </strong>Case report.</p><p><strong>Results: </strong>A 69-year old woman with no history of chronic rhinosinusitis developed complaints of nasal congestion, rhinorrhea, sneezing, and anosmia. These symptoms started after one year of treatment with nivolumab. Pale polyps were observed on fiberoptic endoscopy examination. A gradual increase in eosinophil blood counts was noted. On histopathology, heavy infiltrates of eosinophils were seen in the tissue.</p><p><strong>Conclusions: </strong>Nivolumab is used to treat various advanced metastatic malignancies, with a good safety profile. Nevertheless, physicians must be alert to the possibility of evolving type II inflammation in patients, as appropriate therapy can be provided to improve their quality of life.</p>","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"93-96"},"PeriodicalIF":2.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39623418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Asian Pacific journal of allergy and immunology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1